<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Depending on Results, COVID-19 Vaccine Trials Could End Early
Image Overlay - Depending on Results, COVID-19 Vaccine Trials Could End Early

Depending on Results, COVID-19 Vaccine Trials Could End Early

Depending on Results, COVID-19 Vaccine Trials Could End Early

COVID-19 trials may be stopped early depending on results, says U.S. infectious disease official Anthony Fauci. While clinical trials of 30,000 are expected to continue through the end of 2020, an independent board has the power to cease trials early if the results are unquestionably positive—or negative. Dr. Robert Redfield, director of the U.S. Centers for Disease Control and Prevention notes that it will become clear if a vaccine is effective after about 150 to 175 infections. With over 260,000 square feet of global capacity, more than 20 years of experience, and a success rate of 99.9% delivery on-time and in full, Yourway is the optimal premium courier to entrust sensitive trial materials.

Back to Index
Media

Upcoming Events

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Precision in Clinical Trials Summit (Boston)

May 6-7, 2024
Hilton Boston Park Plaza

Media

Articles

Regulatory barriers in cross-border European pharmaceutical transport

Open chat
Come chat with us!
Hello! How can I help you?